Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.38 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1627897 | 0.86 | PTPRC (0.37) | EGLN1P2RX7EGLN3 | |
| SCHEMBL12720344 | 0.85 | EGLN1 (0.52) | EGLN1P2RX7EGLN3 | |
| SCHEMBL1626938 | 0.85 | EGLN1 (0.46) | EGLN1P2RX7EGLN3KEAP1 | |
| SCHEMBL1627894 | 0.77 | DAGLA (0.30) | — | |
| SCHEMBL12720515 | 0.76 | EGLN1 (0.42) | EGLN1P2RX7 | |
| SCHEMBL12720343 | 0.76 | EGLN1 (0.53) | EGLN1P2RX7EGLN3 | |
| SCHEMBL1627024 | 0.74 | EGLN1 (0.43) | EGLN1P2RX7EGLN3KEAP1EGLN2 | |
| SCHEMBL1626332 | 0.73 | EGLN1 (0.49) | EGLN1P2RX7 | |
| SCHEMBL1626986 | 0.72 | PTPRC (0.42) | EGLN1P2RX7EGLN3 | |
| SCHEMBL1625906 | 0.72 | EGLN1 (0.55) | EGLN1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7635715-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | EGLN2, EGLN3, HIF1AN | EGLN1 4/4885P2RX7 3938/4885EGLN3 2/4885 |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | EGLN2, EGLN3, HIF1AN | EGLN1 4/4885P2RX7 3938/4885EGLN3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.